CIO Bulletin Announces DiaCarta Inc. As One of the 30 Fastest Growing Companies of 2018
RICHMOND, Calif.–(BUSINESS WIRE)–DiaCarta today announced that CIO Bulletin has named it among the 30 Fastest Growing Companies of 2018. The positioning is based on DiaCarta’s revenue growth, financial status, openness to innovation, global collaboration and partnership, flagship products launching, regulatory progress and ability to forecast future business and technology trends. Selecting by a panel of experts and members of CIO Bulletin’s editorial board, the CIO Bulletin 30 Fastest Growing Companies of 2018 is a premier recognition program which identifies companies that have the most innovative approach towards understanding the market trends and exceptional problem-solving techniques in the field of Business and Technology.
“We are glad to name DiaCarta as one of the 30 fastest growing companies of 2018. Realizing a total of $45.0 M USD through its Series B funding round, DiaCarta has made several milestones in the year of 2018 for its development and commercialization of the precision molecular diagnostics products (CE only), including liquid biopsy single gene mutation detection tests, colorectal cancer mutation detection blood test, blood-based radiation therapy toxicity monitoring test, HPV mRNA test, etc. and all the clinical developments,” said J. P. Pande, Editor-in-Chief of the CIO Bulletin Magazine.
“We are honored and thrilled to be recognized by CIO Bulletin as one of the 30 Fastest Growing Companies of 2018,” said Aiguo (Adam) Zhang, CEO and Founder of DiaCarta, “We are moving our business to the next level by putting our flagship products to clinical trials in the U.S., China, and Italy in 2019 and looking forward to serving cancer diagnostic and therapeutic community with our innovations that redefine precision molecular diagnostics.”
DiaCarta is a translational genomics and personalized diagnostics company based in Richmond, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies in molecular diagnostics and clinical genomics. With over 20,000 square feet dedicated to a GMP-compliant lab space as well as CLIA and ISO 13485 certifications, DiaCarta is changing the landscape of molecular diagnostics.
ABOUT CIO BULLETIN
CIO Bulletin is an interactive, preeminent leadership platform serving as a central resource for information on Business & Information Technology (IT) leaders and their entrepreneurial ventures. From celebrating innovation to identifying best practices and providing a forum for today’s CIOs and other technology decision makers, CIO Bulletin aspires to keep its readers informed about how the techie giants, governments and consumers are unfurling organizational innovation in the Business & IT world.
DiaCarta SARS-CoV-2 Test Detecting 3 Viral Genes Receives US FDA Emergency Use Authorization & Test Manufacturing Expanded to 500K COVID-19 Tests/Week
DiaCarta Inc, a precision molecular diagnostic company in CA, announced Thursday the US FDA granted Emergency Use Authorization for DiaCarta’s proprietary QuantiVirus™ PCR diagnostic (Dx) test specifically detecting three different genes of SARS-CoV-2, the virus causing the COVID-19 pandemic. DiaCarta recently expanded manufacturing capacity to 500,000 tests per week and is planning to expand to even larger (4x) scale manufacturing to meet the increasing demand for PCR tests to monitor COVID-19.
DiaCarta Inc. has filed for EUA with the FDA and has received CE mark for its highly sensitive QuantiVirus™ SARS-CoV-2 Test Kit
DiaCarta Inc., a precision molecular diagnostic company, announced today that it has filed for Emergency Use Authorization (EUA) with the US FDA for its QuantiVirus™ SARS-CoV-2 test and has validated the COVID-19 diagnostic test in its own CLIA certified lab in Richmond, CA to provide testing services for healthcare providers and patients. DiaCarta recently received Conformitè Europëenne (CE) Mark for its product.
DiaCarta announced that it is launching a new suite of CE-IVD marked highly sensitive hydrolysis probe (TaqMan-qPCR) based QClamp® assays for detection of common cancer mutations in genes, such as KRAS, NRAS, BRAF, EGFR, PIK3CA and JAK2, using tissue biopsy (FFPE) and liquid biopsy (cfDNA) samples.
DiaCarta, Inc., Awarded $2 Million NCI Contract to Pursue Regulatory Approval of Innovative Cancer Radiation Response Blood Test
DIACARTA, Inc. announced today that it has received a $2 million National Cancer Institute (NCI) Small Business Innovation Research (SBIR) contract to continue development of its RadTox™ cfDNA radiation therapy toxicity monitoring test kit for cancer patients.
DiaCarta has been recognized as one of the Top 10 In-Vitro Diagnostic Technology Solution Providers 2018 by Med Tech Outlook Magazine. The positioning is based on an evaluation of DiaCarta’s specialty in genomic testing for biomarkers, personalized diagnostics and clinical sample testing service provided in their CLIA-certified lab.